Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer
Shinichiro Kashiwagi, Yuka Asano, Wataru Goto, et al.
PLoS ONE (2017) Vol. 12, Iss. 2, pp. e0170634-e0170634
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Spatial Architecture and Arrangement of Tumor-Infiltrating Lymphocytes for Predicting Likelihood of Recurrence in Early-Stage Non–Small Cell Lung Cancer
Germán Corredor, Xiangxue Wang, Yu Zhou, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 5, pp. 1526-1534
Open Access | Times Cited: 212
Deep learning in cancer genomics and histopathology
Michaela Unger, Jakob Nikolas Kather
Genome Medicine (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 24
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
Lironne Wein, Peter Savas, Stephen J. Luen, et al.
Frontiers in Oncology (2017) Vol. 7
Open Access | Times Cited: 105
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Cinzia Solinas, Luisa Carbognin, Pushpamali De Silva, et al.
The Breast (2017) Vol. 35, pp. 142-150
Closed Access | Times Cited: 104
DDTNet: A dense dual-task network for tumor-infiltrating lymphocyte detection and segmentation in histopathological images of breast cancer
Xiaoxuan Zhang, Xiongfeng Zhu, Kai Tang, et al.
Medical Image Analysis (2022) Vol. 78, pp. 102415-102415
Closed Access | Times Cited: 39
Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity
Bo He, Kira H Wood, Zhijie Li, et al.
EMBO Molecular Medicine (2025)
Open Access | Times Cited: 1
MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity
Xin Cheng, Jing Li, Keigo Tanaka, et al.
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 12, pp. 2665-2675
Open Access | Times Cited: 74
Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer
Wataru Goto, Shinichiro Kashiwagi, Yuka Asano, et al.
Anticancer Research (2018) Vol. 38, Iss. 5
Open Access | Times Cited: 72
Multiple modes of action of eribulin mesylate: Emerging data and clinical implications
Javier Cortés, Patrick Schöffski, Bruce A. Littlefield
Cancer Treatment Reviews (2018) Vol. 70, pp. 190-198
Open Access | Times Cited: 68
High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulin—but not with treatment of physician’s choice—in the EMBRACE study
Yasuo Miyoshi, Yuta Yoshimura, Kenichi Saito, et al.
Breast Cancer (2020) Vol. 27, Iss. 4, pp. 706-715
Open Access | Times Cited: 60
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
Ruiwen Ding, Prateek Prasanna, Germán Corredor, et al.
npj Precision Oncology (2022) Vol. 6, Iss. 1
Open Access | Times Cited: 36
Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, et al.
BMC Cancer (2017) Vol. 17, Iss. 1
Open Access | Times Cited: 58
Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer
Nuri Jang, Hee Jung Kwon, Min Hui Park, et al.
Annals of Surgical Oncology (2018) Vol. 25, Iss. 4, pp. 937-946
Closed Access | Times Cited: 49
Significant Association Between Low Baseline Neutrophil-to-Lymphocyte Ratio and Improved Progression-free Survival of Patients With Locally Advanced or Metastatic Breast Cancer Treated With Eribulin But Not With Nab-Paclitaxel
Yoshimasa Miyagawa, Kazuhiro Araki, Ayako Bun, et al.
Clinical Breast Cancer (2018) Vol. 18, Iss. 5, pp. 400-409
Open Access | Times Cited: 47
Molecular Changes in Breast Cancer Induced by Radiation Therapy
Kim Sheva, Sangita Roy Chowdhury, Nataly Kravchenko‐Balasha, et al.
International Journal of Radiation Oncology*Biology*Physics (2024) Vol. 120, Iss. 2, pp. 465-481
Closed Access | Times Cited: 5
Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, et al.
Journal of Translational Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 44
Use of the tumor-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to combination therapy with pertuzumab, trastuzumab, and docetaxel for advanced HER2-positive breast cancer
Koji Takada, Shinichiro Kashiwagi, Wataru Goto, et al.
Journal of Translational Medicine (2018) Vol. 16, Iss. 1
Open Access | Times Cited: 42
Prediction of lymph node metastasis by tumor-infiltrating lymphocytes in T1 breast cancer
Koji Takada, Shinichiro Kashiwagi, Yuka Asano, et al.
BMC Cancer (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 36
Efficacy of Eribulin in Soft Tissue Sarcomas
Edward Phillips, Robin L. Jones, Paul H. Huang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
A new marker for predicting sentinel lymph node metastasis in early (cT1-2N0) breast cancer: Tumor-infiltrating lymphocytes (TILs)
Xiaofei Ni, Weitao Wang, Huimin Sun, et al.
PLoS ONE (2025) Vol. 20, Iss. 3, pp. e0320487-e0320487
Open Access
Tumor-infiltrating lymphocytes associate with outcome in nonendemic nasopharyngeal carcinoma: a multicenter study
Alhadi Almangush, Miia Ruuskanen, Jaana Hagström, et al.
Human Pathology (2018) Vol. 81, pp. 211-219
Open Access | Times Cited: 37
Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer
Natsuko Satomi-Tsushita, Akihiko Shimomura, Juntaro Matsuzaki, et al.
PLoS ONE (2019) Vol. 14, Iss. 9, pp. e0222024-e0222024
Open Access | Times Cited: 33
A Standardized Evaluation Method for FOXP3+ Tregs and CD8+ T-cells in Breast Carcinoma: Association With Breast Carcinoma Subtypes, Stage and Prognosis
Eleni C. Papaioannou, Minas Sakellakis, Maria Melachrinou, et al.
Anticancer Research (2019) Vol. 39, Iss. 3, pp. 1217-1232
Open Access | Times Cited: 32
A maintained absolute lymphocyte count predicts the overall survival benefit from eribulin therapy, including eribulin re-administration, in HER2-negative advanced breast cancer patients: a single-institutional experience
Junichiro Watanabe, Mitsue Saito, Yoshiya Horimoto, et al.
Breast Cancer Research and Treatment (2020) Vol. 181, Iss. 1, pp. 211-220
Open Access | Times Cited: 32
Neutrophil-to-lymphocyte ratio and histological type might predict clinical responses to eriburin-based treatment in patients with metastatic breast cancer
Mayu Myojin, Yoshiya Horimoto, Mayuko Ito, et al.
Breast Cancer (2020) Vol. 27, Iss. 4, pp. 732-738
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top